Brad Power’s Post

🇪🇺 Excited to share the results of our latest European study which focused on the external validation and comparison of MRI-based models predicting the risk of clinically significant prostate cancer. ❓ These predictive models have been integrated into an algorithm developed by the European Association of Urology under the supervion of Hendrik Van Poppel to assist in deciding whether a patient needs a biopsy for the early detection of prostate cancer. 🚀 Our findings provide crucial insights that enhance diagnostic strategies and patient care in the realm of prostate cancer. https://lnkd.in/egGEKQcg

Many non-small cell lung cancer (#NSCLC) patients are diagnosed with advanced or metastatic disease. Despite its success, immune checkpoint inhibitor (ICI) therapy faces challenges such as inconsistent patient responses, the development of resistance, and adverse immune-related effects. A growing body of evidence indicates that epigenetic abnormalities play a crucial role in the onset, progression, and resistance to cancer treatment. In this study published in Clinical & Translational Medicine, the author performed thorough genomic analyses with GeneseeqPrime™ on primary tumor samples obtained from 393 individuals diagnosed with stage III/IV NSCLC. Additionally, the authors incorporated data from three external cohorts for further analysis and validation. The result showed that baseline DOT1L mutations could potentially function as a predictive biomarker for the response to ICIs in NSCLC patients. Read more about the study: https://lnkd.in/gQyE8jQY #NGS #oncology #precisionmedicine #genomics #precisionmedicine #cancergenomics #cancer #precisiononcology #Geneseeq #immunotherapy

NEW in European Urology Oncology: Can we use radiomics to measure fracture risk in prostate cancer? In this study, Ravi B. Parikh, Caleb Hearn, MPH, CAPM, and team validate biomechanical computed tomography (BCT) as an independent predictor of fracture among men with advanced prostate cancer. BCT-assessed bone density was highly concordant with DXA measurements. Given the low use of guideline-directed DXA screening in the real world, BCT of routinely collected CT scans may offer an accurate and convenient means to screen for fracture risk among patients with mHSPC. https://lnkd.in/eMMFJ77d

Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited treatment options. Surgery is the most effective therapy, but few patients qualify. Identifying molecular differences in PDAC is crucial. Two main molecular subtypes, classical and basal-like, have been identified, with different responses to chemotherapy and prognosis. Splicing dysregulation is common in cancer, influencing tumorigenesis. This study identifies a splicing signature distinguishing PDAC subtypes, with subtype-specific splice variants serving as accurate survival predictors. The splicing factor Quaking (QKI) is implicated in the basal-like subtype, controlling a pro-mesenchymal splicing program associated with migration and chemotherapy resistance. High QKI expression correlates with poor outcomes, suggesting it as a reliable basal-like marker with prognostic potential, aiding in patient stratification for treatment selection. Truly remarkable research. https://lnkd.in/ei5EswTT

📃Scientific paper: Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality? Abstract: Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy. Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs. The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity. Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration. This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease. Discover the rest of the scientific article on es/iode ➡️https://etcse.fr/52I

As #InterventionalOncology section editor for Current Oncology Reports, I would like to share an article that is hot off the press! Important work by Ahmad Parvinian, Anil Nicholas Kurup & team from Mayo Clinic on the current status of percutaneous ablation in patients with #sarcoma. Although there is a paucity of high-level evidence specific to sarcomas, ablation techniques are safe & effective for achieving local tumor control & providing pain relief in select patients & are of particular benefit in those with metastatic disease or requiring palliative care. This review article provides treatment strategies in this select patient population. #irad #interventionalradiology Article found at https://lnkd.in/eBhn5T4h Society of Interventional Oncology Society of Interventional Radiology European Conference on Interventional Oncology Cardiovascular and Interventional Radiological Society of Europe Radiological Society of North America (RSNA) Society of Surgical Oncology Sarcoma Foundation of America Sarcoma UK Kick Sarcoma Sarcoma Cancer Care Foundation National Comprehensive Cancer Network® (NCCN®) National Cancer Institute (NCI)

Which operative strategy results in the most favorable long-term health-related quality of life after surgery for esophagogastric junction cancer? Check out this systematic review published this week in DOTE! https://lnkd.in/ddJHrXNY

Our recent work in Oral Diseases! Textbook outcome in oral cancer! TO could be regarded as a guide for quality improvement ！ The TO rate was 35%. Younger age, subsite in buccal area, Charlson Comorbidity Index Score of 0, higher body mass index, higher hemoglobin, higher albumin, and unilateral ND were associated with TO. 5-year OS was 70.5% in overall TO patients and 49.0% in non-TO patients (HR, 0.47; 95% CI, 0.31–0.70; p < 0.001). …. Conclusion: Not achieving TO in oral cancer surgery was associated with worse long-term outcome. TO could be used as a proxy for surgical quality improvement.

What is early Breast cancer? When cancer is found only in the breast or nearby lymph nodes and has not spread to other parts of the body. Once identified, it can be intended to be cured by surgery & chemotherapy or hormonal therapy. CanAssist Breast is a prognostic test for predicting the probability of recurrence in early-stage breast cancer patients and if the patient requires chemotherapy or not. CanAssist Breast is a prognostic test developed by OncoStem that classifies patients as ‘low-risk’ or ‘high-risk’ based on the patient’s risk of breast cancer recurrence over five years. CanAssist Breast provides information about the risk of recurrence of early-stage, hormone receptor-positive breast cancer patients. This test analyses critical biomarkers in the tumour to assess the risk of recurrence and helps oncologists to personalize a treatment plan. Ask your oncologist for more details on CanAssist Breast. #CanAssist #breastcancerawareness #oncostem #EarlyDetectionMatters #BreastCancerAwarenessMonth #CanAssistBreast #BreastCancerSupport #BreastCancerPrognosis #CancerTreatmentOptions #HealthcareTechnology #FightAgainstCancer #PatientCare

Rather than undergo upfront radical cystectomy, select patients with very high-risk nonmuscle-invasive bladder cancer may have sustained response to bacillus Calmette-Guérin (BCG). https://brnw.ch/21wIrLS #blcsm